• Eliminating Pollen Spectral Interference in EEM Fluorescence

  2026-05-24

  Zhang et al. (2024) present a robust machine learning approach to accurately distinguish hazardous bioaerosols by addressing the significant spectral interference caused by pollen in excitation–emission matrix (EEM) fluorescence spectroscopy. Their integration of advanced spectral preprocessing and random forest classification improves hazardous substance detection, establishing a new methodological benchmark for bioaerosol monitoring.

• IGF2BP1-m6A-THBS1 Axis Drives Macrophage Fibrosis in Lungs

  2026-05-23

  This study uncovers how the m6A reader IGF2BP1 promotes pulmonary fibrosis by stabilizing THBS1 mRNA in macrophages, enhancing glycolytic metabolism and M2 polarization through a TLR4-dependent pathway. These findings provide a mechanistic link between RNA modification, macrophage metabolic reprogramming, and fibrotic progression, suggesting new therapeutic targets for lung fibrosis.

• Smurf1 Downregulation Sensitizes Colorectal Cancer to Cispla

  2026-05-22

  This study demonstrates that low expression of Smurf1 significantly enhances the chemosensitivity of colorectal cancer (CRC) to gemcitabine and cisplatin in both cell and patient-derived xenograft models. The findings provide new mechanistic insight for overcoming chemotherapy resistance in CRC by targeting Smurf1, with direct implications for translational oncology research.

• Tamoxifen in Research: Applied Workflows and CreER Innovatio

  2026-05-22

  Tamoxifen stands out as a selective estrogen receptor modulator pivotal for CreER-mediated gene knockout and advanced cancer studies. This article distills experimental protocols, troubleshooting insights, and the translational bridge between immune profiling and genetic engineering, empowering researchers to leverage APExBIO’s high-purity Tamoxifen for reproducible, high-impact results.

• Latrunculin B Inhibitor: Precision Disruption of Actin Dynam

  2026-05-21

  Latrunculin B delivers rapid, reversible actin cytoskeleton disruption, enabling high-resolution studies of cellular actin dynamics. This guide translates bench-proven workflows and troubleshooting strategies, showing how APExBIO’s Latrunculin B unlocks robust, reproducible results in cytoskeletal research.

• Autophagy–Metastasis Signature Predicts CRC Prognosis and Im

  2026-05-21

  Bai et al. (2026) developed a novel prognostic signature for colorectal cancer (CRC) by integrating autophagy and liver metastasis-associated genes, leveraging both bulk and single-cell transcriptomic data. Their risk model provides improved predictive power for patient outcomes and offers mechanistic insight into how autophagy and metastasis contribute to immune evasion, with implications for therapy response and translational research.

• USP7 Modulates Macrophage Polarization via PKM2 in Pancreati

  2026-05-20

  This study uncovers how ubiquitin-specific protease 7 (USP7) regulates macrophage polarization through pyruvate kinase M2 (PKM2)-dependent metabolic reprogramming in severe acute pancreatitis. The findings highlight a novel immunometabolic axis that could be targeted to alleviate inflammation in pancreatitis and potentially other inflammatory conditions.

• MHY1485: Strategic mTOR Activation for Translational Discove

  2026-05-20

  This executive article guides translational researchers in leveraging MHY1485, a powerful mTOR activator and autophagy inhibitor, to dissect cell signaling and disease pathways. Integrating mechanistic insight, competitive positioning, and practical protocol advice, it synthesizes recent evidence—including findings on mTOR modulation in metabolic disease—to shape a forward-thinking research strategy.

• TAK-715: Redefining p38α MAPK Inhibition in Translational Re

  2026-05-19

  This article offers translational researchers a comprehensive perspective on TAK-715, a highly selective p38 MAPK inhibitor, emphasizing its dual-action mechanism, experimental best practices, and future impact on cytokine signaling modulation and anti-inflammatory agent development. By integrating mechanistic findings from recent structural studies with actionable protocol guidance, we outline how TAK-715—available from APExBIO—sets new benchmarks for specificity, efficacy, and translational potential in chronic inflammatory disease research.

• p53/PUMA-Dependent Lethality via WRN Inhibition in MSI Colon

  2026-05-19

  This study reveals that inhibition or loss of Werner (WRN) helicase induces p53/PUMA-mediated apoptosis selectively in mismatch repair-deficient (MSI) colorectal cancer cells. These findings clarify the molecular vulnerability of p53-wildtype MSI CRCs and highlight WRN as a promising synthetic lethality target for precision cancer therapies.

• CHIR-99021 (CT99021): Precision GSK-3 Inhibition in Stem Cel

  2026-05-18

  CHIR-99021 (CT99021) from APExBIO sets the benchmark for selective GSK-3 inhibition, enabling robust modulation of Wnt/β-catenin and TGF-β/Nodal pathways in stem cell pluripotency and differentiation workflows. This article unpacks advanced applications, optimized protocols, and troubleshooting tips to harness its full potential across neuronal, cardiac, and immunological models.

• MOG (35-55) Peptide: Advancing Translational MS Research

  2026-05-18

  This article explores the mechanistic foundation of MOG (35-55) as a gold-standard tool for experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS) research. It synthesizes recent advances in immune signaling, protocol optimization, and translational strategy, offering actionable guidance for researchers seeking to model neuroinflammation and interrogate novel therapeutic pathways. Drawing on fresh mechanistic insights, such as the role of PARP7 inhibition in modulating interferon responses, this piece uniquely bridges molecular immunology with practical EAE model deployment, setting a new bar for rigor and relevance in the autoimmune disease model landscape.

• Y-27632 and the Future of Translational ROCK Inhibition

  2026-05-17

  This article provides a deep-dive, evidence-labeled analysis of Y-27632 as a selective ROCK inhibitor, contextualizing its impact on cytoskeletal dynamics, translational research, and experimental workflows. By integrating mechanistic insights, recent peer-reviewed evidence, and strategic guidance, we position APExBIO’s Y-27632 as a cornerstone for next-generation discoveries in cell biology and disease modeling.

• SHH and FGF10 Control Distinct Urethral Development in Roden

  2026-05-16

  This study provides a comparative analysis of penile development in mice and guinea pigs, revealing that species-specific timing and levels of SHH and FGF10 expression underlie fundamental differences in urethral groove and prepuce formation. These findings have direct implications for understanding human congenital malformations and refining developmental biology models.

• Tamoxifen: Mechanistic Precision and Neuro-Immune Insights i

  2026-05-15

  Explore the mechanistic depth of Tamoxifen as a selective estrogen receptor modulator and its unique role in neuro-immune research. This article offers advanced scientific context and protocol guidance distinct from standard workflow articles.

414 records 8/28 page Previous Next First page 上5页 678910 下5页 Last page